Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

Jonathan Reynolds will lead the new combined Department for Business, Innovation, Science and Trade (DBIST). In the midst of ...

The intense rivalry between Novo Nordisk and Eli Lilly in the market for GLP-1 agonist-based therapies for obesity and type 2 ...

Leela Barham looked at what had happened a year after the NHS 10-Year Plan, released in July 2025, included the commitment to ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, ...

Novartis saw its sales grow 3% in the second quarter, returning to growth after a 1% fall in the first quarter caused by ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and validate drug targets and train AI models used in drug discovery. The first ...

Despite ongoing advancements in genomics, artificial intelligence, and precision medicine, clinical trial success rates have remained low, with approximately 90-95% of drug candidates failing during ...

Three more biotechs have revealed their intentions to list on Nasdaq – BlossomHill, VogenX, and Latigo – as 2026 continues on ...

Lundbeck has completed patient randomisation in a pivotal trial of epilepsy candidate bexicaserin, one of its major growth ...

Bristol Myers Squibb has said it is the first life sciences company to buy a new AI supercomputing infrastructure blueprint ...

In what is thought to be South Korea's largest biopharma acquisition to date, Samsung Biologics has agreed to buy PolyPeptide ...